

Long Term Care Formulary

RS – 33

SECTION	SUBJECT	PAGE			
RESTRICTED USE	calcitonin (Calcimar®) 200 IU/mL injection	1 of 1			
		<b>YY</b>	<b>MM</b>	<b>DD</b>	
		Original	01	06	28
		Revised	03	08	28
		Revised	06	02	23
	Revised	14	01	23	

**Note: January 2014 update removes calcitonin nasal spray from restriction (removed from Canadian market October 2013)**

Calcitonin 200 IU/mL injection is approved for use under the following conditions:

**PROTOCOL 1 – Paget’s Disease**

- Treatment of Paget's disease for patients who do not respond to alternative treatments or for whom alternatives are not suitable; duration of treatment should not exceed 3 months. In exceptional circumstances (e.g. in patients with impending pathological fracture) treatment duration may be extended up to a maximum of 6 months.

**PROTOCOL 2 – Bone Pain Secondary to Recent Osteoporotic Fracture**

- Prevention of bone loss and treatment of bone pain from sudden immobilization associated with recent osteoporotic fractures. Treatment duration should be limited to 2 weeks and not to exceed 4 weeks in any case.

**PROTOCOL 3 – Hypercalcemic Emergencies**

- Early treatment of hypercalcemic emergencies and the treatment of hypercalcemia associated with malignancy

All other uses and indications for calcitonin injectable will required application via the non-formulary/special authorization process.